Veliparib (ABT-888) is a novel oral poly-ADP-ribose polymerase (PARP) inhibitor that is being developed for the treatment of hematologic malignancies and solid tumors. Although the pharmacokinetics of veliparib have been studied in combination with cytotoxic agents, limited information exists regarding the pharmacokinetics (PK) of chronically dosed single-agent veliparib in patients with either BRCA 1/2-mutated cancer or PARP-sensitive tumors. The objectives of the current analysis were to characterize the population pharmacokinetics of veliparib and its primary, active metabolite, M8, and to evaluate the relationship between veliparib and M8 concentrations and poly-ADP-ribose (PAR) level observed in peripheral blood mononuclear cells (PBMCs).Seventy-one subjects contributed with veliparib plasma concentrations,M8 plasma concentrations,and PAR levels in PBMCs.Veliparib and M8 concentrations were modeled simultaneously using a population PK approach. A 2-compartment model with delayed first-order absorption and the elimination parameterized as renal (CL R /F) and nonrenal clearance (CL NR /F) adequately described veliparib pharmacokinetics. The pharmacokinetics of the M8 metabolite was described with a 2-compartment model. Creatinine clearance(CL CR ) and lean body mass (LBM) were identified as significant predictors of veliparib CL R /F and central volume of distribution, respectively. For a typical subject (LBM, 48 kg; CL CR , 95 mL/min), total clearance (CL R /F + CL NR /F), and central and peripheral volume of distribution for veliparib were estimated as 17.3 L/h, 98.7 L, and 48.3 L, respectively. At least 50% inhibition of PAR levels in PBMCs was observed at dose levels ranging from 50 to 500 mg.
with a PARP inhibitor, 6, 7 as these tumors have compromised ability to repair double-stranded DNA breaks, resulting in an accumulation of DNA strand breaks, which are lethal in these cells.
The pharmacokinetics (PK) of veliparib have been characterized in cancer patients. [7] [8] [9] Renal excretion is the primary route of veliparib elimination, with approximately 70% of the administered oral drug excreted as unchanged parent drug via urine in patients. 8 In addition to renal excretion, veliparib is metabolized in the liver by at least 4 cytochrome P450 (CYP450) isoenzymes including CYP2D6, -1A2, -2C19, and -3A4, 10 with CYP2D6 playing the key role in the formation of M8, the primary, active metabolite in humans. 11 PARP inhibition in peripheral blood mononuclear cells (PBMCs) or peripheral blood lymphocytes (PBLs), measured by poly-ADP-ribose (PAR) formation, has been used as a pharmacodynamic biomarker in the development of PARP inhibitors. 8, [12] [13] [14] Significant inhibition of PAR levels in PBMCs was observed in a phase 0 study in patients receiving a single dose of veliparib. 8 In light of a strong rationale that veliparib can be developed as a monotherapy, a clinical study was conducted to evaluate the safety, tolerability, and PK of single-agent veliparib in patients with either BRCA 1/2-mutated cancer or PARP-sensitive tumors. The objectives of this analysis were (1) to characterize the population PK of veliparib and M8 and to assess the potential impact of intrinsic factors on the PK parameters, and (2) to explore the exposure-response relationship for PAR in PBMCs.
Methods
Subjects, Study Design, and Treatment Data were obtained from a phase 1 multicenter, randomized, open-label dose-escalation study (ClinicalTrials.gov Identifier: NCT00892736) evaluating the safety, tolerability, and PK of chronically dosed single-agent veliparib in patients with either BRCA 1/2-mutated cancer or PARP-sensitive tumors. The study protocol was approved by the institutional review boards of the study sites, and written informed consent was obtained from each participant prior to enrollment. The effects of veliparib treatment on the level of PARP inhibition in PBMCs were also determined.
Patients were treated at 1 of 9 different doses of oral veliparib without regard to meals at 50/50, 100/50, 100/100, 150/100, 150/150, 200/200, 300/300, 400/400, and 500/500 mg (AM/PM dosing) twice daily. Only the morning dose was given on day 1, and twice-daily dosing started on day 2 for at least 1 cycle (28 days). About 6 patients (range, 5-16 patients), including at least 1 patient with a known BRCA germ-line mutation, were treated at each dose level.
Sampling and Assay for Veliparib and M8 Serum Concentration Peripheral venous blood samples (4 mL each) were collected on days 1 and 15 of cycle 1 at the following times: before morning dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours post-morning dose administration. For dose 200/200 mg and above, an additional single PK blood draw was obtained just before the sixth dose on day 4. The plasma concentrations of veliparib and M8 were analyzed using a validated liquid chromatographymass spectrometric (LC-MS) assay. 15 Sampling and assay for PAR levels in PBMCs were obtained on consented patients on days 1 and 28 of cycle 1 before the morning dose and 2, 4, 8, and 24 hours post-morning dose. An additional blood draw for PBMCs, collected during cycle 4, was only available for a small proportion of patients. PAR concentration was determined by enzyme-linked immunosorbent assay. 8 
Population Pharmacokinetic Modeling
Software and Estimation Methods. Veliparib and M8 plasma concentration-time data were fitted simultaneously using Phoenix NLME software (version 1.4, build 7.0.0.2535; Certara USA, Inc, Princeton, New Jersey), and the first-order conditional estimationextended least squares method. Data preparation and visualization were performed using R software (version 3.1.1; R Foundation for Statistical Computing). The molecular weights of veliparib and M8 are similar, with a ratio of M8 to veliparib of 1.057. 10 Hence, no corrections for the concentration units were performed, and nanograms per milliliter was used for analysis purposes.
Base Model. Graphical analysis was conducted to assess trends in the data, and 1-and 2-compartment models were investigated to describe the concentrationtime profile of veliparib and M8. Different absorption models (zero-or first-order absorption with or without lag time) were explored. Total clearance for veliparib (CL) was parameterized as renal (CL R ) and nonrenal (CL NR ) clearance; the former was assumed to represent renal excretion and the latter referring to the conversion to metabolites. Using current data, the fraction of veliparib metabolized to M8 (f m ) was not identifiable; however, from the literature, it is known that an average of 70% oral veliparib is renally excreted (f renal = 70%). 8 Thus, veliparib not cleared by renal excretion was assumed to be metabolized into M8 (f m = 1 -f renal = 30%).
Between-subject variability was incorporated using an exponential error structure, as PK parameters are assumed to be log-normally distributed:
where θ i is the estimated parameter value (post hoc value) for individual i, θ TV is the population mean parameter value, and η i is the between-subject random effects for individual i and is assumed to follow normal distribution with a mean of zero and a variance of ω 2 . The structure of random-effect correlations was explored after incorporating covariates into the base model.
Residual variability was tested as additive, proportional, and a combination of the two. Correlation was considered between residual error terms for veliparib and M8 because their quantitation by LC-MS used a single shared internal standard.
After incorporating covariates and correlation between random effects, between-occasion variability (BOV) was also tested, defined for parameter θ in an individual i at occasion j, as shown in equation 2.
where θ ij is the estimated parameter value for the individual i at occasion j, and κ ij is BOV on parameter θ for individual i at occasion j and is assumed to follow a normal distribution with a mean of zero and a variance of π 2 . The BOV was considered because pharmacokinetic sampling was conducted on 2 occasions for each participant, on study day 1 or day 4 of cycle 1 and on study day 15 of cycle 1.
Base model was selected based on likelihood ratio test and standard goodness-of-fit plots, including observed concentrations (DV) versus populationpredicted concentrations (PRED), DV versus individual-predicted concentrations (IPRED), conditional weighted residuals (CWRES) versus PRED, and CWRES versus time after dose plots.
Covariate Model Development. Once the base model was established, the influence of covariates on the PK parameters was explored. Covariate selection was based on physiological relevance, visual inspection of between-subject random effects-covariate relationships, and the likelihood ratio test. In the forward addition and backward elimination process, a decrease or increase of 6.63 units in the objective function value (OFV) for inclusion or exclusion of 1 parameter was considered statistically significant (df = 1; α = 0.01). The covariates that were screened included age, total body weight (WT), lean body mass (LBM), 16 body surface area (BSA), creatinine clearance (CL CR ), sex, and liver function (ALT, AST, and total bilirubin). CL CR and BSA were estimated using the Cockcroft-Gault and Mosteller formulas, 17, 18 respectively. Continuous covariates (age, WT, LBM, BSA, liver function, and CL CR ) and categorical covariate (sex) were investigated as shown in equations 3 and 4, respectively.
In equation 3, cov i is the value of the covariate in individual i, cov med is the median value in the population, and θ cov is the slope factor describing the effect of the centered covariate on parameter θ as a power relationship.
In equation 4, cov i is the value of the covariate in individual i, which was coded as 0 for females and 1 for males.
Population Model Qualification. The final model was qualified with a visual predictive check (VPC), quantitative predictive check (QPC), 19 and nonparametric bootstrap analysis. The final model was evaluated using VPC by comparing the observed 5th, 50th, and 95th percentiles of concentration-time profiles with the simulated percentiles obtained from 500 replicates. QPC was performed by graphically overlaying the observed 50th percentiles of C max and AUC derived from noncompartmental analysis (NCA) on the distribution of the 50th percentiles derived from 500 final model simulated replicates. AUC calculation was performed by Phoenix WinNonlin, following its AUC methodology. 20 The predictability of the final model was deemed acceptable if the observed median C max and AUC were in the middle of the distribution of model derived percentiles. Similarly, QPC comparing the observed 25th and 75th percentiles with the corresponding distribution of simulated percentiles was also performed. In addition, the robustness of the final model parameter estimates was checked by comparing the model predicted estimates with the bootstrap estimates (n = 250).
Evaluations of PAR Levels in PBMCs
Baseline and post veliparib administration PAR levels were measured in PBMCs as indicated previously. PARP inhibition in PBMCs was expressed as a percentage of PARP activity after veliparib administration in subjects. Quintile plots 21 were made to explore the veliparib concentration-response relationship for PAR in PBMCs, where the concentrations are divided into 5 equal bins, and mean PAR response in each bin and the 95% confidence interval are plotted against the mean veliparib concentration in the corresponding bin. As PK and PBMC samples were not collected simultaneously, model-predicted individual veliparib and M8 plasma concentrations at PBMC sampling points were used as a pharmacokinetic endpoint, and PARP inhibition was defined as the percentage of predose baseline PAR levels.
Results
A population PK model was developed using veliparib (n = 1214) and M8 (n = 656) concentrations obtained from 67 patients with BRCA 1/2-mutated cancer or PARP-sensitive tumor types (Supplemental Figure S1) . A total of 295 PAR concentrations from 41 patients were available for pharmacodynamic (PD) analysis. The demographic and clinical characteristics of the patient population included in the PK/PD analysis are summarized in Table 1 . For a few patients (n = 20), the estimated CL CR with the Cockcroft-Gault formula 17 exceeded 120 mL/min. Their CL CR was assumed to be 120 mL/min as a physiologically reasonable upper limit of CL CR in adults. The population PK model was developed for veliparib and its metabolite, M8, simultaneously. A 2-compartment model with first-order absorption and lag time adequately described the concentration-time profile of veliparib. In comparison with a 1-compartment model, a 2-compartment model decreased the OFV by 173 units (df = 4, P < .001; Supplemental Table S1 ) and improved the goodness-of-fit plots, thus was considered as the structural model. The M8 PK was adequately described with a 2-compartment model. Figure 1 shows the schematic of the simultaneous drugmetabolite model used to describe the PK of veliparib and M8. Between-subject variability was estimated on K a , tlag, V c /F, V p /F, CL R /F, CL NR /F, V c_met , CL met , and V p_met , whereas that on Q and Q met was not estimated in the final model. Correlation between random effects of CL NR /F, CL R /F, and V c /F decreased the OFV by 64 units but worsened the parameter precision and increased the condition number to 10 8 . Hence, it was dropped from further analysis. The proportional plus additive residual error model best accounted for the unexplained variability of the observed concentrations for veliparib and M8. The expected correlation between residual errors of parent and metabolite because of sampling from the same matrix was accounted for using a fixed-effect correlation term (Table 2) .
Clinically relevant covariates that depicted a definitive trend with the random effects of the PK parameters were evaluated using forward addition and backward elimination. LBM and CL CR on V c /F and CL R /F, respectively, were found to be significant covariates ( OFV = −23 and OFV = −11, respectively; df = 1, P < .01; Supplemental Table S1 ). The coefficient for the effect of LBM on V c /F and CL CR on CL R /F were estimated to be 1.21 and 0.903, respectively, close to a linear relationship. Covariates explained 17% and 16% of the variability on CL R /F and V c /F, respectively, relative to the base model. Supplemental Figure S2 shows that the inclusion of covariates in the final model accounted for the trend observed between the random effects of veliparib PK parameters and LBM and CL CR in the base model. Adding BOV to the model did not result in a significant decrease in OFV and hence was not included. Table 2 shows the parameter estimates for the final model. The final equations for the typical values of CL R /F, CL NR /F, and V c /F were as follows:
where mL/min is the unit of CL CR . Notes: The final equations for the typical values of CL R /F, CL NR /F, and V c /F were as follows:
) power C L cr , where mL/min is the unit of CL CR .
) power L BM , where kg is the unit of LBM. The proportional residual error for M8 is expanded as: CMultStdev·Ratio·MultStdev, where MultStdev is the coefficient variation for proportional error for M8 and the value (%CV) was fixed as 100%. %RSE was calculated from bootstrap results.
where kg is the unit of LBM.
The final model-predicted PK profile in representative individuals and the goodness-of-fit plots are shown in Figures 2 and 3 and Supplemental Figure S3 , respectively. The individual predicted concentrations for veliparib and M8 are in good agreement with the observed concentrations. In order to evaluate the precision of estimated PK parameters, a non-parametric bootstrap analysis was performed. The population estimates of the final model showed close agreement with the median obtained from the bootstrap replicates and were within the 2.5th to 97.5th percentiles obtained from bootstrap (Table 2) , indicating model stability. Figure 4 shows the VPC of the final model. There is a substantial overlap between the 5th, 50th, and the 95th percentiles of the observed and the simulated data indicating the simulated data from the final model can reproduce the observed data. However, for M8, there were minor overpredictions at the 95th percentile of the observed data. Similar results were observed for QPC, that the observed C max and AUC were at the center of predicted distribution of the 25th, 50th, and 75th percentiles of C max and AUC from 500 replicated datasets for both veliparib and M8, indicating the final model could predict the central tendency as well as the variability of the observed data adequately ( Figure 5 and Supplemental Figure S3-10) . Figure 6 depicts the concentration-response relationship for PAR in PBMCs. Inhibition of PAR by ß50% compared with the predose baseline was observed in patients treated at the 50/50 mg dose, and the inhibition of PARP gradually increased to ß70% when the dose increased to 500/500 mg.
Discussion
Veliparib is a potent oral PARP inhibitor, and it has been predominantly studied in combination with cytotoxic agents and radiation therapy for the treatment of a wide range of malignancies. [7] [8] [9] [22] [23] [24] However, limited information exists regarding the PK and PD of chronically dosed single-agent veliparib in patients with either BRCA 1/2-mutated cancer or PARP-sensitive tumor types. Based on data from a phase 1 clinical trial, we developed a simultaneous population PK model for veliparib as well as its primary, active metabolite, M8. An effect of increasing CL R /F and V c /F with increasing CL CR and LBM, respectively, was identified, and CL CR and LBM were added as covariates in the final model. The PD analysis used PAR as the PD biomarker, 8, 12, 13 and inhibition of PAR level was observed in PBMCs.
Individual model predictions of representative parent-metabolite PK profiles (Figures 2 and 3) , goodness-of-fit plots (Supplemental Figure S2) 23 and on population PK analysis by Salem et al (20.9 L/h and 173 L, respectively) or by Li et al (13. 3 L/h and 126 L, respectively) using a 1-compartment model. 9, 25 In our case, the superiority of a 2-compartment model was Figure 4 . Visual predictive check (VPC) for 500 replicated datasets for veliparib (top) and M8 (bottom). The black lines represent the 5%, 50%, and 95% observation intervals, and the red lines represent the 5%, 50%, and 95% prediction intervals.
well indicated by a decrease of OFV and improvement of goodness-of-fit plots. Dose proportionality in dose level from 50 to 500 mg was supported here, and no induction or suppression of its own clearance was associated with chronic dosing of veliparib. Negligible accumulation was observed within the dose range tested using the NCA approach (article in preparation).
Given that about 70% of veliparib was recovered in the urine as unchanged in cancer patients receiving a 50-mg single oral dose, 8 it is not surprising that renal function, measured with estimated creatinine clearance, was identified as the predictor on the CL R /F, which explained 17% of the between-subject variability. A similar finding has recently been reported by Salem et al from population PK analysis of 325 patients with solid tumors, 9 in which creatinine clearance was modeled with the exponent of 0.48 on oral clearance. The predominant role of renal function on veliparib clearance was supported by Li et al by a physiologically based pharmacokinetic (PBPK) model integrated with a mechanistic kidney module. 25 According to our covariate model, patients with mild (ß25% decrease in CL CR ) and moderate (ß50% decrease in CL CR ) renal function are associated with ß10% and ß20% increase in veliparib exposure, respectively. Whether patients with renal impairment need dose adjustment will rely on the tolerability profile of veliparib with therapeutic dose in targeted patient populations. An ongoing phase 1 study in cancer patients with renal dysfunction will shed light on the impact of varying degrees of renal dysfunction (NCT01366144). After adding CL CR on CL R /F, none of the other patient demographic measures, such as body weight, LBM, or age, were identified as significant covariates because of possible collinearity with CL CR .
Instead of total body weight, LBM was found to be a significant covariate and was considered in explaining veliparib PK variability on V c /F, similar to that reported previously. 9 Given the hydrophilic nature of veliparib, 26 our finding supported the results of studies for hydrophilic drugs, that a better correlation between LBM and volume of distribution than body weight has been found. LBM has been proposed as a better predictor of drug dosage, especially in obese patients. 27 Nearly 60% of the patients included in our study were either overweight or obese (BMI of 25 or larger). Therefore, the use of LBM over body weight on V c /F could be attributed to the more accurate description of LBM for the difference in body composition in our patient population.
To date, no report with respect to the volume of distribution of M8 or the fraction of veliparib converted to M8 has been published. We assumed that veliparib not cleared by renal excretion was metabolized to M8. An average of 70% of veliparib oral doses was excreted as the unchanged parent drug in the urine in cancer patients 8 ; thus, the remaining 30% was assumed to be converted to M8 by CYP2D6 metabolism. Furthermore, on the basis of results from an in vitro study that CYP2D6 accounts for ß72% of overall veliparib metabolism, 10 we expected that the "true" fraction converted to M8 might be 22%, that is, 30% (percent of nonrenal elimination of veliparib) × 72%.
The CYP2D6 polymorphism was not determined for the current study. Based on simulations from a PBPK model, CYP2D6 poor metabolizers exhibited ß20% higher exposure and the ultraextensive metabolizers had ß20% lower exposure in comparison with the extensive metabolizers. 25 Given that CYP2D6 metabolism contributes to ß22% of veliparib total clearance, changes in CYP2D6 activity caused by polymorphism is likely to have insignificant influence on veliparib PK. The impact of CYP2D6 deficiency, when collectively evaluated with other factors (ie, LBM and CL CR ), has the potential to be clinically meaningful and needs further evaluation.
PARP inhibitors are believed to have adequate activity as monotherapy in tumors with defects in homologous recombination such as those with BRCA mutation or PARP-sensitive cancer types.
14 PARP inhibition in surrogate samples, including PBMCs or PBLs, reflects the inhibition of PAR formation in tumor tissues and thus has been widely used in the development of PARP inhibitors. [12] [13] [14] In the present analysis, with increases in veliparib and M8 concentrations, a trend in decreases in PAR levels in PBMCs was observed. We attempted to quantitate the exposure-PAR relationship with the concentrations of veliparib as driver for PAR reduction using an E max model, assuming a direct effect between exposures and PAR reduction. A similar structure model was reported by Wang et al to describe the inhibitory effect of rucaparib, a novel PARP inhibitor, on PAR formation. 13 However, an extremely low IC 50 (30 ng/mL) was estimated with low precision. The doses studied were higher such that PAR inhibition was approaching a plateau even with the lowest dose. The estimated IC 50 was higher than the lower limit of quantification for veliparib (10 ng/mL), but limited data were available in the range of 10-30 ng/mL. Therefore, only exploratory exposure-PAR results are presented. The concentration of the parent was used as driver because it has been reported that M8 is approximately 5-fold less potent compared with veliparib. 28 Furthermore, the concentrations of veliparib and M8 are correlated. Exposure-PAR in PBMC relationships needs to be further characterized and ideally when applied with cytotoxic agents, which would be expected to increase the level of PARP activity susceptible to inhibition by veliparib. The exposure-PAR relationship depicts the mechanism of action of veliparib. However, the relationship between level of PAR inhibition and efficacy is unknown, as shown in the case of approved PARP inhibitors such as rucaparib and olaparib. 
Conclusions
In conclusion, we characterized the PK of veliparib and M8, the primary, active metabolite, using data collected in patients with BRCA 1/2-mutated cancer or PARPsensitive tumors and evaluated the effect of patient demographics and clinical factors on veliparib PK parameters. CL CR and LBM were identified as significant predictors of veliparib CL R /F and V c /F, respectively. The exploratory PK/PD analysis demonstrated that veliparib inhibits PAR levels in PBMCs, supporting the intended mechanism of action.
